Product
DZD8586
3 clinical trials
2 indications
Indication
lymphomaIndication
Non-HodgkinClinical trial
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult ParticipantsStatus: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)Status: Not yet recruiting, Estimated PCD: 2027-04-30